OTCMKTS:BTCY Biotricity (BTCY) Stock Price, News & Analysis → Biden out June 13; Kamala won’t replace him? (From Paradigm Press) (Ad) Free BTCY Stock Alerts $1.34 -0.03 (-2.20%) (As of 04:17 PM ET) Add Compare Share Share Today's Range$1.27▼$1.3550-Day Range$0.92▼$1.6352-Week Range$0.70▼$4.37Volume43,260 shsAverage Volume84,700 shsMarket Capitalization$12.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC Filings Get Biotricity alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Biotricity Stock (OTCMKTS:BTCY)Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Read More BTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTCY Stock News HeadlinesApril 20, 2024 | investing.comBiotricity launches cardiac monitoring pilot with hospital groupMarch 8, 2024 | finance.yahoo.comAre Medical Stocks Lagging HCA Healthcare (HCA) This Year?May 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).February 22, 2024 | morningstar.comBiotricity Inc BTCYFebruary 22, 2024 | benzinga.comBiotricity Stock (NASDAQ:BTCY) Earnings Dates and Earning CallsFebruary 19, 2024 | benzinga.comBiotricity's Earnings OutlookFebruary 19, 2024 | finance.yahoo.comBiotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21stFebruary 3, 2024 | msn.comBiotricity Inc. Faces Potential Nasdaq Delisting ThreatMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).January 23, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion HeartbeatsJanuary 23, 2024 | finance.yahoo.comBiotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion HeartbeatsNovember 20, 2023 | msn.comHC Wainwright & Co. Downgrades Biotricity (BTCY)November 14, 2023 | msn.comBiotricity reports Q2 resultsNovember 13, 2023 | benzinga.comEarnings Outlook For BiotricityNovember 2, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Releases Another Groundbreaking Product: Biotres ProOctober 31, 2023 | finance.yahoo.comBiotricity Releases Another Groundbreaking Product: Biotres ProOctober 10, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart DeviceOctober 10, 2023 | finance.yahoo.comBiotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart DeviceOctober 4, 2023 | finanznachrichten.deBiotricity, Inc.: CORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres DeviceOctober 4, 2023 | finance.yahoo.comCORRECTION BY SOURCE: Biotricity Announces Patent Filing for Cutting-Edge Biotres DeviceSeptember 29, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Could Be Riskier Than It LooksAugust 28, 2023 | usatoday.comWhy Biotricity and Waqaas Al-Siddiq are Revolutionizing Modern HealthcareAugust 20, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q1 2024 Earnings Call TranscriptAugust 15, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business UpdatesAugust 15, 2023 | finance.yahoo.comBiotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business UpdatesAugust 14, 2023 | finance.yahoo.comBiotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15thAugust 11, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Shows Continued Growth and Strength in its Fundamentals on its Path to ProfitabilitySee More Headlines Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/02/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolOTCMKTS:BTCY CUSIPN/A CIK1630113 Webwww.biotricity.com Phone(650) 832-1626FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,660,000.00 Net Margins-163.11% Pretax Margin-163.11% Return on EquityN/A Return on Assets-252.90% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.14 Sales & Book Value Annual Sales$11.63 million Price / Sales1.11 Cash FlowN/A Price / Cash FlowN/A Book Value($2.67) per share Price / Book-0.51Miscellaneous Outstanding Shares9,420,000Free Float6,963,000Market Cap$12.91 million OptionableNot Optionable Beta1.51 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Waqaas Al-Siddiq Ph.D. (Age 39)Founder, President, CEO & Chairman Comp: $732kMr. S. John Ayanoglou (Age 57)Chief Financial Officer Comp: $305.75kMr. Andy WongVice President of OperationsDr. George N. NikopoulosDirector of Business DevelopmentMr. Matt ZabelVice President of Sales & StrategyMr. Amir AliChief Development OfficerMore ExecutivesKey CompetitorsAinosOTCMKTS:AIMDXylo TechnologiesNASDAQ:MDGSMIRA PharmaceuticalsNASDAQ:MIRAPharmChemOTCMKTS:PCHMRedHill BiopharmaNASDAQ:RDHLView All Competitors BTCY Stock Analysis - Frequently Asked Questions How have BTCY shares performed in 2024? Biotricity's stock was trading at $1.15 at the start of the year. Since then, BTCY stock has increased by 13.0% and is now trading at $1.30. View the best growth stocks for 2024 here. How were Biotricity's earnings last quarter? Biotricity, Inc. (OTCMKTS:BTCY) issued its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.07. The firm earned $2.97 million during the quarter, compared to analyst estimates of $3 million. When did Biotricity's stock split? Shares of Biotricity reverse split on the morning of Monday, July 3rd 2023. The 1-6 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Biotricity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biotricity investors own include Axsome Therapeutics (AXSM), Bank of America (BAC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Broadcom (AVGO), Cannabix Technologies (BLOZF), BioLineRx (BLRX), CV Sciences (CVSI) and Charlotte's Web (CWBHF). How do I buy shares of Biotricity? Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BTCY) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerTrump just won 2024Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.